The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia

Molecular Psychiatry

Volumn 1, Issue 1, 1996, Pages 54-58

  Dean, B ^a   Crook, J M ^a,b   Opeskin, K ^a,c   Hill, C ^a   Keks, N ^a,c   Copolov, D L ^a  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ALFRED HOSPITAL   (Australia)

Author keywords

Acetylcholine; Clozapine; Extrapyramidal side effects; Muscarinic receptors; Schizophrenia

Indexed keywords

CLOZAPINE; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT;

ADULT; AGED; ANIMAL; ARTICLE; AUTORADIOGRAPHY; CAUDATE NUCLEUS; CHEMISTRY; DRUG EFFECT; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PUTAMEN; RAT; SCHIZOPHRENIA;

ADULT; AGED; ANIMALS; ANTIPSYCHOTIC AGENTS; AUTORADIOGRAPHY; CAUDATE NUCLEUS; CLOZAPINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PUTAMEN; RATS; RECEPTORS, MUSCARINIC; SCHIZOPHRENIA;

EID: 0030091175     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Tandon R, Mann NA, Eisner WH, Coppard N. Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients. Psychiatry Res 1990; 31: 235-241.
2. Caradoc Davies G, Menkes DB, Clarkson HO, Mullen PE. A study of the need for anticholinergic medication in patients treated with long-term antipsychotics. Aust NZ J Psychiatry 1986; 20: 225-232.
3. Davis KL, Berger PA. Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis. Biol Psychiatry 1078; 13: 23-49.
4. Karson GN, Casanova MF, Kleinman JE, Griffin WST. Choline acetyltransferase in schizophrenia. Am J Psychiatry 1993; 150: 454-459.
5. Bracha HS, Kleinman JE. Postmortem neurochemistry in schizophrenia. Psychiatr Clin North Am 1986; 9: 133-141.
6. Owen F et al. Neurotransmitter receptors in brain in schizophrenia. Acta Psychiatr Scand Suppl 1981; 291: 20-28.
7. Watanabe S, Nishikawa T, Takashima M, Toru M. Increased muscarinic cholinergic receptors in prefrontal cortices of medicated schizophrenics. Life Sci 1983; 33: 2187-2196.
8. Yeomans JS. Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology 1995; 12: 3-16.
9. Snyder SH, Greenberg D, Yamamura HI. Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry 1974; 31: 58-61.
10. Ashton H. Brain Function and Psychotrophic Drugs. Oxford Medical Pub: Oxford, 1992, pp 315-317.
11. Baldessarini RJ, Frankenburg FR. Clozapine: a novel anti-psychotic agent. New Eng J Med 1991; 324: 746-754.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder, 3rd edn, revised. The American Psychiatric Press: Washington DC, 1987.
13. Tandon R, Greden JF. Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Arch Gen Psychiatry 1989; 46: 745-753.
14. Marder SR, Van Putten T. Who should receive clozapine? Arch Gen Psychiatry 1988; 45: 865-867.